You are here

Article Text

Article menu
Download PDFPDF
Editorial
Cognition enhancing drugs (‘nootropics’): time to include coaches and team executives in doping tests?
  1. Ryan M Rodenberg,
  2. John T Holden
  1. Florida State University, Tallahassee, Florida, USA
  1. Correspondence to Dr Ryan M Rodenberg, Florida State University, 139 Chieftan Way, Tallahassee 32306-4280, Florida, USA; rrodenberg{at}fsu.edu

https://doi.org/10.1136/bjsports-2015-095474

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The use of brain boosting drugs by athletes has been well documented and testing for such cognition enhancing drugs is now implemented. Largely absent from the purview of antidoping agencies, however, is the drug testing of coaches and team executives. This editorial introduces commonly used nootropics (drugs that influence cognition) and describes their on-label effects. We then examine the off-label uses of these drugs and consider whether sport organisations, if they are genuinely determined to eliminate performance enhancing drugs among all participants, should also incorporate the testing of coaches and team executives. Advances in sport analytics have changed coaching and executive roles, with decision-making acumen more important than ever.

    Brain enhancing drugs including modafinil (Provigil), methylphenidate (Ritalin), and dextroamphetamine (Adderall) were developed to treat sleep problems, attention deficit disorders (ADD), memory …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.